帕金森病与非类固醇抗炎药物的关系;系统性审查和元分析
Amal Mohammad Badawoud1, Lashin Saad Ali2,3, Mahmoud S Abdallah4,5
1Department of Pharmacy Practice, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, Saudi Arabia.
Frontiers in pharmacology
|August 19, 2024
概括
非类固醇抗炎药物 (NSAIDs),特别是布洛芬和非阿司匹林NSAIDs,可能会降低患帕金森病 (PD) 的风险. 然而,在本研究中,阿司匹林与PD风险降低没有显著的关联.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种与衰老相关的神经退行性疾病,其特征是运动缺陷和增加的神经炎症.
- 临床前研究表明,非类固醇抗炎药物 (NSAIDs) 可能在帕金森病模型中提供神经保护.
研究的目的:
- 系统地审查和分析现有文献,以澄清NSAID使用与帕金森病发展之间的关联.
- 解决关于NSAID消费和PD发生率的矛盾发现.
主要方法:
- 在Scopus,PubMed和Web of Science数据库中进行了全面的文献搜索,以寻找NSAID和PD发生率的研究.
- 数据使用Review Manager 5.4.1中的随机效应模型进行统计分析,以95%的置信区间计算聚合赔率比率 (OR).
- 评估的结果包括使用NSAIDs,布洛芬,阿司匹林和非阿司匹林NSAIDs的患者的PD发展.
主要成果:
- 在使用NSAIDs (OR=0.88),ibuprofen (OR=0.73) 和非阿司匹林NSAIDs (OR=0.85) 的患者中观察到PD风险的统计显著降低.
- 在阿司匹林使用和患帕金森病的风险之间没有发现统计学意义上的关联.
结论:
- 布洛芬,非阿司匹林NSAID和一般的NSAID使用可能与帕金森病风险降低有关.
- 根据目前的证据,阿司匹林摄入似乎与PD发展的修改风险无关.
相关概念视频
Parkinson's Disease: Treatment
240
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
240
Parkinson's Disease: Overview
501
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
501
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K


